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Abstract
Background: Internet-based self-management (IBSM) support cost-effectively improves asthma control, asthma
related quality of life, number of symptom-free days, and lung function in patients with mild to moderate persistent
asthma. The current challenge is to implement IBSM in clinical practice.
Methods/design: This study is a three-arm cluster randomized trial with a cluster pre-randomisation design and
12 months follow-up per practice comparing the following three IBSM implementation strategies: minimum
strategy (MS): dissemination of the IBSM program; intermediate strategy (IS): MS + start-up support for professionals
(i.e., support in selection of the appropriate population and training of professionals); and extended strategy
(ES): IS + additional training and ongoing support for professionals. Because the implementation strategies
(interventions) are primarily targeted at general practices, randomisation will occur at practice level.
In this study, we aim to evaluate 14 primary care practices per strategy in the Leiden-The Hague region, involving
140 patients per arm. Patients aged 18 to 50 years, with a physician diagnosis of asthma, prescription of inhaled
corticosteroids, and/or montelukast for ≥3 months in the previous year are eligible to participate. Primary outcome
measures are the proportion of referred patients that participate in IBSM, and the proportion of patients that have
clinically relevant improvement in the asthma-related quality of life. The secondary effect measures are clinical
outcomes (asthma control, lung function, usage of airway treatment, and presence of exacerbations);
self-management related outcomes (health education impact, medication adherence, and illness perceptions); and
patient utilities. Process measures are the proportion of practices that participate in IBSM and adherence of
professionals to implementation strategies. Cost-effective measurements are medical costs and healthcare
consumption. Follow-up is six months per patient.
Discussion: This study provides insight in the amount of support that is required by general practices for
cost-effective implementation of IBSM. Additionally, design and results can be beneficial for implementation of
other self-management initiatives in clinical practice.
Trial registration: the Netherlands National Trial Register NTR2970
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Background
Asthma is a common chronic inflammatory disease of
the airways, typically characterized by symptoms such as
wheeze, shortness of breath, and coughing [1]. Despite
the wide availability of effective therapy, long-term man-
agement of asthma falls for short of the goals set in
guidelines [2], and many patients do experience a pro-
found burden of disease [3].
Self-management is an essential component in the
proactive management of asthma [1,4] because it helps
patients to reach their treatment goals and enables
patients to manage symptoms, treatment, physical and
psychosocial consequences, and lifestyle changes inher-
ent in living with a chronic condition [5]. However, the
uptake of self-management in clinical practice may be
hampered because easy-use tools that enhance sustained
uptake of action plan usage by patients are lacking in
today’s practice [6], and patients can experience a lack of
ownership of these action plans [7]. Not surprisingly, a
minority of general practices provide patients with writ-
ten action plans [8,9].
Internet technology is increasingly being seen as an
appealing tool for self-management for patients with
chronic disease [10-12]. Telehealth care in asthma is
defined as healthcare being delivered from a distance,
facilitated electronically, and involving the exchange of
information through the personalized interaction be-
tween a healthcare professional using their skills, judg-
ment, and the patient providing information [13].
Telehealth care may overcome barriers towards optimal
care in patients with mild to moderate asthma [14].
More specifically, internet technology can be employed
for ongoing individualized management of the patient
[15].
Internet-based self-management (IBSM) support in
asthma consists of the following components: internet-
based asthma monitoring, internet-based goal setting,
decision support with a treatment plan, online medical
review, tailored online information, and communica-
tion with a healthcare provider. Recently, we have
shown that such IBSM can improve asthma-related
quality of life, asthma control, the number of
symptom-free days, and lung function in patients with
mild to moderate persistent asthma, as compared to
usual care [16]. In a cost-utility analysis [17], it was
demonstrated that IBSM support can be as effective as
current asthma care with regard to quality of life in
terms of patient utilities, and costs are similar over a
one-year period.
Therefore, the current challenge is to implement IBSM
support in routine asthma management within primary
care. Patients that are most likely to be willing to partici-
pate and benefit from (internet-based) self-management
are those with partially controlled or uncontrolled
asthma [18-20]. These patients constitute about two-
thirds of the asthma population in primary care [8].
A structured implementation strategy is needed to in-
corporate IBSM in current clinical practice and subse-
quently into a patient’s daily life. Implementation
strategies for IBSM, consisting of several components
(so-called ‘multi-faceted implementation strategy’) are
suggested to be more effective in changing current clin-
ical practices [21]. In addition, tailoring the implementa-
tion strategy to barriers and facilitators experienced by
the target group—patients with asthma, practice nurses
(PNs), and general practitioners (GPs)—is recommended
[22-24]. Such barriers can be identified at different levels
of healthcare system [25]: innovation, the individual pa-
tient (i.e., illness perceptions), professional level, societal
context (opinion of colleagues), organisational context
(organisation of care process), and economic and polit-
ical contexts.
Prior to this project, we conducted focus groups and
interviews with patients and professionals for exploring
barriers and facilitators for usage of IBSM in primary
care [26]. These barriers were identified at patient and
professional/organizational level. Main barriers at the
patient level were unawareness of their level of asthma
control and subsequent possibility for improvement, and
patients often do not perceive asthma as a chronic con-
dition and experience difficulties of integrating self-
management activities into daily life. Main barriers at
the professional level (PN, GP) and organizational level
were unawareness of the level of asthma control of
patients, lack of structure of asthma care, and lack of
structure of routine asthma consultations within general
practice and lack of time. Consequently, we developed
three implementation strategies (the strategies will be
described in more detail below):
1. Minimum strategy (MS): dissemination of the IBSM
program.
2. Intermediate strategy (IS): MS + start-up support for
professionals (i.e., support in selection of the
appropriate population and training of professionals).
3. Extended strategy (ES): IS + additional training and
ongoing support for professionals.
In summary, the MS strategy has not been tailored to
previously identified barriers and corresponds with com-
monly used implementation strategies (i.e., dissemin-
ation of the innovation only). This is in contrast with the
IS strategy, which specifically have been developed for
addressing previous identified barriers. The ES strategy
is the most extensive and time-intensive strategy. Cur-
rently, there are only sparse data on the effectiveness
and cost-effectiveness of implementation strategies for
IBSM in primary care. This information is particularly
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important for the time-intensive implementation inter-
ventions, such as selection of the appropriate population,
professional training, and ongoing support for profes-
sionals in IBSM support.
Hypotheses
To evaluate the impact of these three different imple-
mentation strategies for IBSM in current clinical prac-
tice, we have proposed four hypotheses, which are
constructed to compare the effect of tailoring implemen-
tation strategies to identified barriers (IS and ES) versus
a commonly used, non-tailored strategy (MS):
1. More general practices will participate in IBSM in
the IS or ES strategy as compared with the MS
strategy;
2. The proportion of referred patients who participate
in the IBSM program in the ES or IS strategy will be
greater as compared with the MS strategy;
3. The proportion of referred patients who participate
in the IBSM program in the ES or IS strategy will be
greater as compared to the MS strategy;
4. The ES and the IS strategy will be more cost-effective
as compared to the MS strategy.
Objectives
The objectives of this study are to investigate the effect-
iveness and cost-effectiveness of a MS strategy, as com-
pared to an IS strategy and an ES strategy in a three-
arm, cluster randomized trial. Because these different
implementation strategies have a sequence of effects, the
evaluation is aimed to assess to what extent: practices
participate in IBSM; IBSM improves asthma related
quality of life; patients participate in IBSM; and the vari-
ous implementation strategies are cost-effective.
Methods
Study design
This study is a three-arm, cluster randomized trial with
a cluster pre-randomisation design [7] (Figure 1). Be-
cause the implementation strategies are primarily tar-
geted at general practices, randomisation will occur at
practice level (CONSORT guidelines for cluster trials,
Table 1 [27]). Prior to obtaining informed consent from
GPs and patients, practices will be allocated to one of
the strategies. Follow-up per practice is 12 months. At
patient level, follow-up duration is six months. In the ES
and IS strategies, individual patient outcomes will be
evaluated at baseline (first visit of a patient to the
Figure 1 Study design.
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Table 1 Consort checklist [27]
Item Standard Checklist item
Title Identification of study as
randomised
Implementation strategies of internet-based asthma self-management support in usual care.
Study protocol of the IMPASSE study - a cluster randomized trial
Trial design Description of the trial design
(e.g., parallel, cluster, non-inferiority)
Cluster-randomized trial with a cluster pre-randomization design.
Methods
Participants Eligibility criteria for participants
and the settings where the data
were collected
Eligibility criteria for general practices:
Location within the Leiden - the Hague region. General practitioner/practice nurse that is
willing and available to support patients in internet-based self-management.
Patient eligibility criteria: Age 18 to 50 years; a doctor diagnosis of asthma; prescription of
inhaled corticosteroids and/or montelukast ≥ three months within 12 months prior to
enrolment; internet access; ability to understand written and oral Dutch instructions. Patient
exclusion criteria: Severe co-morbidities, daily or alternate day oral corticosteroid therapy for
≥1 month prior to entering the study and being primarily under treatment by a respiratory
physician.
Data will be collected in a research module of the internet-based self-management support
program (PatientCoach.nl) using web-based questionnaires (SurveyGizmo, Boulder, Colorado).
Interventions Interventions intended for each
group
Internet-Based Self-Management (IBSM) support program :
PatientCoach.nl consists of both a generic web-based system and an instruction visit for
patients. PatientCoach includes modules for self-monitoring (asthma control and lung
function), a treatment plan (medication,), motivational feedback, e-consultation, personalized
information (i.e., inhalation technique), reminders and forums for patients and professionals.
PatientCoach has been developed by the LUMC. Patient Coach will be integrated in the
general practice information system. Additionally PatientCoach contains a research module
which consists of electronic versions of questionnaires.
General practice level
The implementation strategies for internet-based self-management support are primarily
targeted general practices:
1. Minimum strategy (MS): dissemination of the IBSM program.
2. Intermediate strategy (IS): MS + start-up support for professionals (i.e., support in selection
of the appropriate population and training of professionals).
3. Extended strategy (ES): IS + additional training and ongoing support for professionals.
All general practices will be asked to invite at least 10 patients to participate in PatientCoach.
Follow-up duration at general practice level is one year.
Patient level:
Instruction visit on how to use PatientCoach, particularly focusing the essential self-
management skills in asthma (i.e., monitoring, inhalation technique). Patients will be
instructed to monitor their level of asthma control at least once per month, preferably once
weekly using the Asthma Control Questionnaire. General practices themselves can decide
whether the practice nurse and/or general practitioner guide patients in using PatientCoach.
Follow-up per patient is six months. However, patients will have the possibility to continue
using PatientCoach.nl after this period.
Objective Specific objective or hypothesis The objectives of this study are to investigate the effectiveness and cost- effectiveness of a
Minimum strategy, as compared to an Intermediate strategy and an Extended strategy in a
three arm cluster-randomized trial. Since these different implementation strategies have a
sequence of effects, the evaluation is aimed to assess to what extent: 1. practices participate
in IBSM (practice level); 2. IBSM improves asthma related quality of life (patient level);
3. patients participate in IBSM (patient level); and 4. The various implementation strategies are
cost-effective (societal/organisational level)
Outcome Clearly defined primary outcome
for this report
Primary outcome measures are a) the proportion of referred patients that participate in IBSM
(general practice (cluster) and patient level) and b) the proportion of patients that have
clinically relevant improvement in the asthma-related quality of life as measured by the
Asthma Quality of Life Questionnaire [30].Patient usage of IBSM is defined as two out of three
months ACQ-monitoring compliance.
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general practice for instruction on IBSM), and three and
six months after a patient’s start with IBSM. Individual
patient outcomes in the MS strategy will be evaluated at
six months (end-point evaluation) after a patient’s start
with IBSM.
Recruitment of general practices and patients
Eligibility criteria general practices
All general practices located within the Leiden – the
Hague region and a GP/PN that is willing and available
to support patients in IBSM will be eligible. Additionally,
at least one GP per practice needs to give consent for
participation.
Patients
General practices will be asked to invite at least ten 10
patients per practice to participate in IBSM. Based on
previous studies on asthma within general practice, we
know this is feasible [16]. Those patients not willing to
participate in IBSM will be asked informed consent to
participate in an endpoint evaluation at six months.
Informed consent will be obtained during a consultation
with a patient’s PN or GP.
Endpoint evaluation
Patients in practices randomized to the MS strategy, and
those patients in the IS and ES strategy not willing to
participate in IBSM support, will only be approached for
an endpoint evaluation at six months after their start
with PatientCoach.
Eligibility criteria patients
Patients, age 18 to 50 years, with a doctor diagnosis of
asthma and prescription of inhaled corticosteroids and/or
montelukast for at least three months in the previous
Table 1 Consort checklist [27] (Continued)
Randomisation How participants were allocated
to interventions
As the implementation strategies (interventions) are primarily targeted at general practices,
randomisation will occur at practice level.
General practices (i.e., 2,300 patients per ‘standard practice’) are the unit of randomisation.
Prior to informed consent all general practices in the Leiden-the Hague region will be
allocated to one of the three strategies (1:1:1 ratio). General practices receive a letter with
information on the allocated strategy and an invitation to participate in the project.
Randomization will be conducted by Jacob Sont using a computer-generated, permuted-
block scheme. Practices will be stratified according the following characteristics: postal code
(area) and practice size (practices with < 4 general practitioners are defined as a small practice,
practices with ≥4 general practitioners as a large practice.
General practices will be enrolled by Moira Bakker, Johanna van Gaalen and Jiska Snoeck-
Stroband. Patients will be enrolled by general practices.
Blinding
(masking)
Whether or not participants,
care givers, and those
assessing the outcomes were
blinded to group assignment
All general practices and patients are blinded to group allocation. Researchers are not blinded
for group allocation.
Results
Numbers
randomized
Number of participants
randomized to each group
For all three strategies, 12 general practices (clusters) will be recruited, involving 10 patients
per practice to be invited for using PatientCoach per general practice.
Recruitment Trial status Recruitment of patients is ongoing
Numbers
analysed
Number of participants analysed
in each group
Not applicable.
Outcome For the primary outcome, a result
for each group and the estimated
effect size and its precision
Not applicable.
Harms Important adverse events or side
effects
Not applicable.
Conclusions General interpretation of the results This study provides insight in the amount of support that is required by general practices for
cost-effective implementation of IBSM. Additionally, design and results can be beneficial for
implementation of other self-management initiatives in clinical practice.
Trial
registration
Registration number and name of
trial register
the Netherlands National Trial Register NTR2970
Funding Source of funding This study is supported by grants from: - The Netherlands Organisation for Health Research
and Development (ZON-MW 80-82315-97-10004) - The Netherlands Asthma Foundation (NAF
3.4.09.011) - Funding for this publication was obtained from the Netherlands Organisation for
Scientific Research (NWO) Incentive fund Open Access publications - - Hand-held electronic
lung function meters for patients (PikO-1, Ferraris Respiratory, Hertford, United Kingdom) were
provided by GlaxoSmithKline (GSK), Zeist, the Netherlands
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year who have access to the internet are eligible to
participate.
Exclusion criteria patients
Those who have severe co-morbidities (i.e., terminal ill-
ness or a severe psychiatric disease), daily or alternate
day oral corticosteroid therapy for at least a month be-
fore entering the study, or who are primarily under
treatment by a respiratory physician are not eligible. Fur-
thermore, the IBSM support program is not suitable for
those who are unable to understand written and oral
Dutch instructions.
Blinding and strategy allocation
General practices (i.e., 2,300 patients per ‘standard prac-
tice’) will be the unit of randomisation. Practices will be
stratified according the following characteristics: postal
code (area) and practice size (practices with <4 GPs are
defined as a small practice, practices with ≥4 GPs as a
large practice). Prior to informed consent, practices will
be randomized into one of the strategies (1:1:1 ratio), in
order to assess the participation level of practices per
strategy. Practices will receive a letter containing infor-
mation on the allocated implementation strategy and an
invitation to participate in the project.
Both practices and patients will be blinded to group al-
location. Researchers will not be blinded for group allo-
cation. Randomisation will be conducted by Jacob Sont
using a computer-generated, permuted-block scheme.
General practices will be invited until enough practices
per strategy are participating. General practices will be
enrolled by Moira Bakker, Johanna van Gaalen, and Jiska
Snoeck-Stroband. Patients will be enrolled by general
practices.
Sample size calculation
The sample size is based on patient participation in
IBSM (primary outcome). We assume that one-third of
the 15% to 20% of patients who have a written action
plan [9] are actually using it to conduct self-
management activities. Assuming that with the MS, 5%
of the patients are frequently using the IBSM to monitor
their asthma, we will consider the IS and ES successful if
an increase of 25% is achieved (alpha 0.05 and beta
0.20). Using a correction for clustering of patients in
practice (intra-cluster correlation coefficient: 0.25), we
calculated that we need 10 patients in each of 42 prac-
tices 14 practices in the MS, IS, and ES, respectively to
be invited to participate in IBSM using PatientCoach.
This gives a total of 420 patients.
IBSM support program
The IBSM support program consists of both a generic
web-based system and an instruction visit for patients.
PatientCoach
Patientcoach.nl is a generic web-based system that sup-
ports self-management of patients with a chronic condi-
tion. It includes modules for coaching, personalized
information (i.e., inhalation technique), self-monitoring,
reminders, treatment plan, (motivational) feedback, e-
consultations and a forum. PatientCoach has been devel-
oped by the Leiden University Medical Centre (LUMC)
[16]. The program includes options for weekly assess-
ment of the level of asthma control [28,29] and a
quarterly-assessment of asthma-related quality of life
[30]. Furthermore, it offers tools for professionals and
patients, to help them to incorporate IBSM respectively
into routine asthma care and daily life, such as: reminder
options for home monitoring by ACQ and lung func-
tion; reminder options for routine consultations (i.e.,
digital agenda); reminder options (i.e., a general agenda)
for regional educative sessions on asthma, i.e., hosted by
the patient association of the Netherlands Asthma asso-
ciation; and a forum for professionals.
PatientCoach contains a research module that consists
of electronic versions of questionnaires for assessment
of quality of life [31], health education impact [31], self-
reported medication adherence [32], illness perceptions
[33] and costs [34].
Self-management support session for patients on
PatientCoach
Patients participating in PatientCoach will be supported
by their PN and/or GP. PNs will be asked to invite the
patient for at least one consultation (double-consultation)
that aims to inform patients on how to use PatientCoach,
particularly focusing the essential self-management skills
in asthma (i.e., monitoring, inhalation technique).
Usual care
PNs in all strategies will be asked to conduct follow-up
on patients in concordance with the Dutch guideline for
general practice on asthma in adults, which recommends
a medical review and treatment adjustment every two to
four weeks in unstable asthma and medical review once
or twice a year for patients whose asthma is not under
control [35]. The guideline states that routine asthma
consultations include assessment of asthma control,
medication, adverse events, adherence, and measure-
ment of lung function. The guideline is concordant with
current international guidelines, such as the Global Ini-
tiative for Asthma guideline [1].
Implementation strategies
The implementation period is divided in a start-up and
an execution phase (Tables 2 and 3).
All strategies consist of patient-directed (i.e., reminders
for consultations), professional-directed (i.e., training of
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professionals, support on patient selection), and organisa-
tional components (i.e., helpdesk).
Minimum strategy (MS)
Start-up phase basic components
Practice recruitment: practices receive an information
letter on IBSM support by using PatientCoach. Practices
will receive a reminder letter within four weeks.
Participating physicians will be asked whether their
non-responding colleagues in their practices would be
interested in participation. On meetings for professional
groups and patient organisations PatientCoach team
members will present information on self-management
and web-based support.
Patient recruitment: GPs are asked to invite at least
ten patients to use PatientCoach.
PatientCoach information session for participating
practices: In addition to a general announcement, pro-
fessionals receive a manual on PatientCoach. Profes-
sionals (GP and/or PN) have the opportunity to join a
PatientCoach information session. This information ses-
sion is focused on the principles and usage of the IBSM
program by the PN and patients, including home meas-
urement of lung function as forced expiratory volume in
one second (FEV1) using an electronic hand-held spir-
ometer (PiKo-1: Ferraris; Hertford, UK). Finally, a short
on-site training in usage of the PatientCoach system fo-
cusing on integration within the local primary care infor-
mation system is offered to practices.
Execution phase basic components
Practices have access to a web-based helpdesk for tech-
nical issues. For issues related to IBSM in asthma, pro-
fessionals can consult the PatientCoach team by email
and/or telephone.
Intermediate strategy (IS)
This includes a start-up support package that is add-
itional to the components of the MS in the start-up
phase. During the execution phase the IS does not differ
from the MS.
Start-up support package
The start-up support intermediate package consists of:
Practice recruitment. General practices receive an invita-
tion letter that includes all components of the Start-up
Support Implementation strategy. Non-responding prac-
tices receive a reminder letter within four weeks and if
necessary, practices are phoned.
On-site support for patient recruitment. PatientCoach
team members offer practices the opportunity to make a
patient selection in the patient registries of participating
GPs.
PatientCoach start-up training. PNs and GPs are
invited for an interactive session (duration: two hours)
with colleagues. In this session, professionals are stimu-
lated to discuss with each other on how to apply IBSM
in their own practice. This training is focused on a pro-
active attitude toward patients and supporting them in
their self-management skills by using IBSM support:
1. Exploration of a patient’s knowledge about asthma,
illness perceptions [36,37], and the ability to integrate
(internet-based) self-management activities into their
Table 2 Overview of implementation strategies
Implementation
strategy*
MS IS ES
Start-up phase
Practice recruitment
Recruitment letter X X X
Reminder (letter) X X X
Reminder (telephone) X X
PatientCoach information
Manual X X X
Information session X X X
On site instruction X X
Workshop professionals X X X
Patient recruitment
By general practice X X X
On site support (patient selection/invitation) X X X
PatientCoach tools
Reminders X X X
Execution phase
Continuing support
Follow-up by the practice coach team X
Outreach visit (if necessary) X
Workshop professionals (implementation issues) X
Helpdesk
Technical issues (web-based/phone) X X X
IBSM related issues (phone) X X X
* MS =Minimum strategy; IS = Intermediate strategy; ES = extended strategy;
IBSM = internet-based self-management support program (PatientCoach).
Table 3 Study phases and time schedule
Planning
(months)
Start-up phase 6
- General practice recruitment/Instruction general practices 6
- Patient recruitment
Execution phase 6
- Patient follow-up
Follow-up per general practice (includes both start-up and
execution phase period)
12
van Gaalen et al. Implementation Science 2012, 7:113 Page 7 of 11
http://www.implementationscience.com/content/7/1/113
daily life; i.e., by exploring difficulties and discussing
solutions.
2. Asthma control: assessment of the level of asthma
control; patients are invited to discuss their most
recent ACQ-score. Reasons for poor asthma control
in patients are discussed, and the subsequent
management strategy will be discussed.
3. Medication: information on side-effects; instruction,
exploration of therapy adherence, and checking
correct inhaler technique.
4. Asthma related lifestyle: smoking cessation,
avoidance of triggers, regular exercise;
5. Asking about and treating rhinitis, which is known to
influences asthma outcomes [38].
Extended strategy (ES)
The ES does not differ from the IS during the start-
up phase. However, this strategy includes a patient
coach package that is additional to the components of
the MS/IS during the execution phase.
Execution phase
Practice coach package
The practice coach package consists of the following
components:Ongoing support: follow-up by Patient-
Coach team members at one, three, and five months
after baseline by email, telephone, or face-to-face. Dur-
ing these planned consultations, members of the Patient-
Coach team will explore whether practices experience
difficulties. Solutions and future recommendations are
given. An outreach visit [23,39], both PatientCoach team
initiated (planned) or professional initiated (unplanned),
will be conducted when necessary.
Interactive session with professionals: within three
months after starting to use PatientCoach, professionals
will have the opportunity to participate in an interactive
session with colleagues. This session will be focused on
identifying problems for PatientCoach implementation,
and solutions will be discussed.
Measurements and outcomes
Primary outcome measures are the proportion of re-
ferred patients that participate in IBSM and the pro-
portion of patients that have clinically relevant
improvement in the asthma-related quality of life as
measured by the Asthma Quality of Life Questionnaire
[30]. Patient usage of IBSM is based on monitoring of
the level of asthma control using the Asthma Control
Questionnaire [28,29]; monitoring of ACQ during two
out of three months ACQ-monitoring compliance.
Patient level
Demographic characteristics (i.e., educational level,
atopy, smoking status, and symptom-free days) are
obtained at baseline (Table 4). The effect evaluation
includes clinical outcomes (asthma control, lung func-
tion, usage of airway treatment, and the presence of
exacerbations) and self-management related outcomes
(health education impact, self-reported medication ad-
herence and illness perceptions) and patient utilities
(asthma symptom utilities).
Asthma control is using the 7-item Asthma Control
Questionnaire (ACQ), the optimal cut-point for ‘con-
trolled’ is ≤0.75 and a value of ≥1.50 confirms ‘not con-
trolled’ asthma [28]. Lung function will be measured as
the Forced Expiratory Volume in one second (FEV1).
Patients receive a handheld electronic spirometer (PiKo-
1: Ferraris; Hertford, UK) and are instructed to report
the highest value of three measurements in the morning
before taking medication [1]. The presence of exacerba-
tions is assessed; they are defined as deterioration in
asthma that required emergency treatment or
hospitalization (collected by quarterly questionnaire) or
the need for oral steroids for three days or more
(collected by pharmacy records) or the need for oral
steroids for asthma as judged by the attending physician.
Exacerbations are defined according to ATS/ERS state-
ment [40]:
Severe exacerbations require at least one of the follow-
ing: systemic corticosteroids (tablets, suspension, or in-
jection) usage or an increase from a stable maintenance
dose, for three or more days; or a hospitalization or
emergency room visit because requiring systemic
corticosteroids.
Moderate exacerbations require ≥ 1 of the following
features, lasting for two or more days: deterioration in
Table 4 Outcome measures
0 Months 3 Months 6 months /
end-point
Demographic characteristics A N
Clinical
Asthma control (ACQ) A A,N
Lung function (FEV1) [] A A A
Quality of life/patient utilities
Asthma related quality of life
(AQLQ)
A A A,N
Utilities: (EQ-5D) X X A,N
Self-management
Education (HeiQ) X X, N
Medication adherence (MARS) X X X
Illness perceptions (B-IPQ) X X
Costs
Healthcare and other costs
(CostQ)
X X X, N
A = all strategies; X = Intermediate and Extended strategy;
N = non-participating practices.
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symptoms, deterioration in lung function, and/or
increased rescue bronchodilator use.”
Health education impact is assessed by the health edu-
cation impact questionnaire (heiQ) [41]. Self-reported
medication adherence is measured by the Medication
Adherence Report Scale [32]. Illness perceptions are
assessed by using the Brief Illness Perception Question-
naire (Brief IPQ) [33]. In addition, asthma symptom util-
ities are obtained from the Asthma Quality of Life
Questionaire (AQLQ) [42], EQ-5D [31,43] and a visual
analogue scale (VAS).
Professional and organizational level
Characteristics of general practices are assessed, includ-
ing information on area, type of practice, years of estab-
lishment, age of GPs, and structure of asthma care. PN
characteristics include gender, age, education, and years
of experience with asthma consultations. The process
evaluation contains outcomes on the adherence of pro-
fessionals to the implementation strategy and can be
considered as a feasibility evaluation. Attendance to
training sessions of professionals is registered. Active re-
ferral of patients by professionals to PatientCoach is
registered as active participation of practices. Actual
treatment advice by the care provider and the treatment
advice by the system are registered. Furthermore, fre-
quency and time of IBSM usage by care providers are
digitally logged.
Economic evaluation
The economic evaluation includes outcomes on cost-
effectiveness and cost-utility. Medical costs, such as pre-
scribed medication are assessed from electronic patient
records (with written patient permission) complemented
with the patient’s report on medication purchased else-
where [44]. In addition, actual treatment advice by the
care provider and treatment advice by the system are
registered. Healthcare consumption, absenteeism and
productivity loss, and the number of limited activity days
are measured by using the Cost Questionnaire [34]. Fur-
thermore, data on patient contacts (frequency of in-
practice routine asthma consultations, telephone/email
consultations, and unscheduled visits) are registered.
Analysis
The analysis is carried out on an intention-to-treat basis.
Analyses include descriptive statistics and comparisons
on process and effect evaluation. Differences are com-
pared between implementation strategies using a
random-effects analysis accounting for within-patient
repeated measurements and clustering on general prac-
tice, or nonparametric comparisons, such as chi-square,
as appropriate. All data are analyzed using STATA.
Analysis of clinical data
The number of patients with a clinically relevant im-
provement in asthma-related quality of life is based on
a minimal clinical importance of difference (MCID) of
0.5 for the AQLQ [30].Patient utilities: asthma symp-
tom utilities are obtained from the AQLQ [42]; indirect
utilities from the general public are obtained using the
EQ-5D [31,43]. This allows the calculation of quality-
adjusted life years (Qalys). In the base case analysis,
Qalys are estimated using societal utilities obtained
using the Dutch EQ-5D tariff [45]. For sensitivity ana-
lyses, Qalys are estimated using a VAS (transformed
using a power transformation). Data on healthcare pro-
vider utilization and other related costs provide input
for calculation of the contract price that GPs will have
to negotiate for this improved service. Ideally, this is in
the form of a primary care diagnosis and treatment
standard fee.
Economic evaluation
The economic evaluation compares differences in soci-
etal costs to differences in the number of limited activity
days (CEA) and quality-adjusted life years (CUA). The
analysis has a six-month time horizon, without discount-
ing. Group averages are statistically compared using
two-sided bootstrapping and net-benefit analyses are
used to compare costs to patient outcome. Sensitivity
analyses are performed on the perspective (societal ver-
sus healthcare perspective) and the applied utility meas-
ure (Dutch EQ5D, VAS).
Cost-effectiveness
Cost-effectiveness of treatment strategies is evaluated by
incremental net-benefit analysis [46]. Net health benefit
addresses cost-effectiveness ratios by assuming values
for the willingness to pay per unit of effectiveness. The
cost analysis includes both medical (medication, visits,
and hospitalizations) and non-medical costs (productiv-
ity losses, informal care). Other costs are estimated using
quarterly cost questionnaires [34] Costs are valued
according to standard prices charges [47] including time
and travel costs.
Discussion
This study is designed to investigate the effectiveness
and cost effectiveness of implementing IBSM by com-
paring three different implementation strategies (MS, IS,
and ES) in a three-arm cluster-randomized trial with a
cluster pre-randomization design. The IBSM application
contains functionalities that are characterized by some
innovative aspects, such as options for e-consultation
and integration of results into the general practice sys-
tem. These functionalities address previously stated
requirements for both patients and professionals. The
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findings of this study will lead to recommendations for a
potential cost-effective strategy that can be used for the
implementation of IBSM in practice.
This study has been designed for translation of re-
search findings into actual practice. Primarily, the pre-
cluster randomization design allows us to study the ef-
fect of the different implementation strategies on the
number of primary care practices that participate in
IBSM. Second, the impact of the different strategies at
both professional and patient level on actual implemen-
tation (i.e., participation, patient outcomes, and cost-
effectiveness). Third, general practices are given a
leading role to adapt and internalize IBSM in clinical
practice: the project team will only act as facilitators to
these practices. Additionally, the influence of research
activities on implementation has been incorporated in
the design of this study, because these might function
as an extra stimulus for both practices and patients to
adapt and internalize IBSM during the study period.
Therefore, the content of the MS strategy is not only
similar to commonly used (non-tailored) implementa-
tion strategies, but also the number and amount of re-
search activities are minimized. This is in contrast to
the IS and ES strategies, which are specifically designed
to address previous identified barriers. These differ-
ences give us the opportunity to study how much sup-
port is required by general practices for IBSM
implementation. Finally, this study evaluates the costs
of the implementation from a societal perspective,
which is in contrast to other implementation studies
[18,48]. Therefore, we will include costs for asthma
care from both non-participating practices and non-
participating patients.
Implications
The results of this study will help to determine the most
effective way of implementing IBSM. Both the pre-
cluster randomization and the inclusion of the IS and ES
strategies provide a more detailed view of the implemen-
tation process and thereby direction to the focus for fu-
ture implementation processes in primary care. For
example, it may provide information on: the quality and
intensity of support professionals need to identify eli-
gible patients; whether it is sufficient to focus only on
the start-up period of implementation; and whether con-
tinuing support of professionals has additional value in
maintaining implementation.
The results of this study can enhance a broad imple-
mentation of IBSM in current clinical care, based on a
cost-effective strategy. Thereby it can contribute to
improved care for patients with asthma. Furthermore,
design and results of this trial can contribute to develop-
ment of effective implementation strategies for self-
management initiatives for other chronic diseases.
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